Loading stock data…
PLSE
$20.83-0.34 (-1.61%)
Market ClosedLast close May 1
Pulse Biosciences, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pulse Biosciences, Inc. in the Healthcare sector is trading at $20.83. The stock is currently 21% below its 52-week high of $26.30, remaining 21.2% above its 200-day moving average. Technical signals show neutral RSI of 58 and bearish MACD signal, explaining why PLSE maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 58) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$20.83
Potential Upside
5%
Whystock Fair Value$21.87
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.66B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.69
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-84.34%
Volume
Today's trading volume
222,647
Recent News
Pulse Biosciences Trials And Conference Spotlight Reframe Pulse Field Ablation Story
Pulse Biosciences (NasdaqCM:PLSE) has enrolled the first patients in its US pivotal trial for the nPulse Cardiac Catheter System following FDA IDE approval. The nPulse Cardiac Catheter and clinical data are set to be featured in late breaking sessions and live demonstrations at the upcoming Heart Rhythm Society Annual Meeting. These milestones mark progress for the company’s pulse field ablation technology within the electrophysiology community. Pulse Biosciences focuses on applying its...
Pulse Biosciences (PLSE) Enrolls Its First Patients in a Pivotal Atrial Fibrillation Trial
Pulse Biosciences, Inc. (NASDAQ:PLSE) is one of the must-buy small cap stocks to buy. On April 7, Pulse Biosciences, Inc. (NASDAQ:PLSE) announced that it had enrolled the first patients in NANOPULSE-AF. This is the company’s US clinical trial testing the nPulse Cardiac Catheter System as a treatment for occasional episodes of irregular heart rhythm that […]
Pulse Biosciences Initiates Patient Enrollment in NANOPULSE-AF Study
PLSE begins patient enrollment in NANOPULSE-AF pivotal study, advancing its NPS tech toward potential AF treatment approval and entry into a large cardiac market.
Can Pulse Biosciences’ (PLSE) New AF Study and C-Suite Hires Reframe Its PFA Strategy?
Pulse Biosciences recently advanced its nPulse Cardiac Catheter Ablation System by enrolling the first patients in its pivotal NANOPULSE-AF IDE study for drug-resistant paroxysmal atrial fibrillation, while also strengthening its leadership team by appointing Liane Teplitsky as Chief Operating Officer and expanding Dr. David Kenigsberg’s role as full-time Chief Medical Officer. This combination of clinical progress and experienced leadership oversight across clinical, regulatory, quality,...
Pulse Biosciences hires Liane Teplitsky as COO
The appointment gives a former Abbott leader oversight of efforts to bring a pulsed field ablation device to market.